Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 12/20 | 0.43 |
| ▸ | MMP3 | P08254 | 11/20 | 0.43 |
| ▸ | MMP2 | P08253 | 9/20 | 0.43 |
| ▸ | MMP9 | P14780 | 8/20 | 0.43 |
| ▸ | MMP8 | P22894 | 4/20 | 0.43 |
| ▸ | MMP13 | P45452 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.42 |
| ▸ | MMP7 | P09237 | 3/20 | 0.42 |
| ▸ | MMP14 | P50281 | 2/20 | 0.42 |
| ▸ | TNF | P01375 | 2/20 | 0.42 |
| ▸ | MMP20 | O60882 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | MMP10 | P09238 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293013 | 1.00 | CA1 (0.47) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL1176010 | 1.00 | CA1 (0.47) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL15776181 | 0.87 | CA1 (0.42) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL1174310 | 0.85 | CA1 (0.41) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL7897117 | 0.85 | CA1 (0.41) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL8422673 | 0.85 | CA1 (0.41) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL13051146 | 0.84 | ADAM17 (0.48) | MMP1MMP3MMP2MMP9MMP8 | |
| SCHEMBL21834858 | 0.84 | CA1 (0.50) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL8410837 | 0.83 | CA1 (0.46) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL1213869 | 0.83 | CA2 (0.46) | CA1CA2CA7CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3668832-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | Allergan, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-111225900-A | 3, 4-disubstituted 3-cyclobutene-1, 2-diones and their use | 阿勒根公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
| US-8859538-B2 | Uses of substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | CA1 2038/4885CA2 1096/4885CA7 1536/4885 |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CNR2, CNR1, TRPV1 | CA1 1241/4885CA2 343/4885CA7 708/4885 |
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CA1 2921/4885CA2 3341/4885CA7 1090/4885 |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | CA1 2921/4885CA2 3341/4885CA7 1090/4885 |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CA1 2921/4885CA2 3341/4885CA7 1090/4885 |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CA1 2921/4885CA2 3341/4885CA7 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.